| __timestamp | Dynavax Technologies Corporation | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 10811000 |
| Thursday, January 1, 2015 | 22180000 | 33001000 |
| Friday, January 1, 2016 | 37257000 | 64936000 |
| Sunday, January 1, 2017 | 27367000 | 99909000 |
| Monday, January 1, 2018 | 64770000 | 127724000 |
| Tuesday, January 1, 2019 | 74986000 | 161524000 |
| Wednesday, January 1, 2020 | 79256000 | 182933000 |
| Friday, January 1, 2021 | 100156000 | 219982000 |
| Saturday, January 1, 2022 | 131408000 | 278139000 |
| Sunday, January 1, 2023 | 152946000 | 309799000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, effective cost management is crucial for sustaining innovation and growth. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Ultragenyx's SG&A expenses surged by approximately 2,765%, reflecting its aggressive expansion and investment in operational capabilities. In contrast, Dynavax's expenses grew by about 760%, indicating a more measured approach to scaling operations.
The year 2023 marked a significant milestone, with Ultragenyx's expenses peaking at nearly double those of Dynavax. This trend underscores the differing strategic priorities of these companies, with Ultragenyx focusing on rapid growth and Dynavax maintaining a balanced cost structure. As the biotech landscape evolves, these insights offer a window into the financial strategies shaping the industry's future.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Dynavax Technologies Corporation
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.